Literature DB >> 24689108

Increased levels of serum amyloid A during the early phase of hepatitis C treatment with interferon are associated with sustained virologic response - a pilot study.

Michael Gschwantler1, Melisa Dulic2, Emina Dulic-Lakovic2, Remy Schwarzer2, Franz Rieder3, Wolfgang Graninger3, Christoph Steininger3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24689108      PMCID： PMC5712216     

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN： 1841-8724            Impact factor:   2.008


× No keyword cloud information.
  8 in total

1.  Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system.

Authors:  Muriel Lavie; Cécile Voisset; Ngoc Vu-Dac; Virginie Zurawski; Gilles Duverlie; Czeslaw Wychowski; Jean Dubuisson
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

2.  Human serum amyloid A protein inhibits hepatitis C virus entry into cells.

Authors:  Zhaohui Cai; Lei Cai; Jieyun Jiang; Kyung-Soo Chang; Deneys R van der Westhuyzen; Guangxiang Luo
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

3.  Serum amyloid A protein in acute viral infections.

Authors:  H Miwata; T Yamada; M Okada; T Kudo; H Kimura; T Morishima
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

4.  Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Authors:  Peter Ferenci; Hermann Laferl; Thomas-Matthias Scherzer; Andreas Maieron; Harald Hofer; Rudolf Stauber; Michael Gschwantler; Harald Brunner; Christoph Wenisch; Martin Bischof; Michael Strasser; Christian Datz; Wolfgang Vogel; Karin Löschenberger; Petra Steindl-Munda
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

5.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Authors:  Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

6.  Correlations between serum amyloid A protein and C-reactive protein in infectious diseases.

Authors:  A Lannergård; A Larsson; P Kragsbjerg; G Friman
Journal:  Scand J Clin Lab Invest       Date:  2003       Impact factor: 1.713

7.  Aymptomatic CMV viremia is associated with increased levels of serum amyloid A in patients with advanced HIV-infection.

Authors:  Christoph Steininger; W Graninger; A Zoufaly; B Zöllner; H-H Feucht; M Kundi; I Stahmer; H-J Stellbrink; J van Lunzen
Journal:  Eur J Med Res       Date:  2008-06-24       Impact factor: 2.175

8.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.